Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aqua takes over US rights to Verdeso Foam from Stiefel
Indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged three months and more, Verdeso foam is emollient-based, ethanol-free and unavailable in generic form.
Indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged three months and more, Verdeso foam is emollient-based, ethanol-free and unavailable in generic form.
The oral, once-daily androgen receptor inhibitor is indicated for treating metastatic castration-resistant prostate cancer patients, who were previously treated with docetaxel therapy, in the setting of medical or
Binosto, which provides fracture-risk reduction at the hip & spine, is claimed to be the first and only buffered solution used in the treatment of osteoporosis. EffRx chairman
Neutralizing a pro-inflammatory molecule known as interleukin-6 (IL-6), the new antibody is expected to represent a significant improvement compared to existing agents that have already entered clinical trials
The sale follows execution of an agreement signed between both the companies in March 2013 and marks K&F’s commitment to expand its operational presence and customer base across
The memorandum of understanding, which was signed on 28 July 2011, was concluded following mutual consent from both the companies and to enable Fujifilm to realign its long-term
The trial did not discover new safety signals, while the median OS for patients in the lapatinib and chemotherapy group was 12.2 months against 10.5 months for patients
Other companies scheduled to be fined include Merck, Arrow, Generics UK, Resolution Chemicals, Alpharma, A.L. Industrier and Xellia. Without disclosing the exact amount of fine imposed, sources close
The entire TrialOne suite, including Sample Tracking, Direct Data Capture, and Subject Recruitment & Screening, will be implemented to create standardized workflow across all clinics. OmniComm CTO Randy
Under the randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC), patients treated with combination of iniparib and chemotherapy could not achieve